A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy

Annals of Surgical Oncology

Volumn 11, Issue 8, 2004, Pages 731-738

  Finkelstein, Steven E ^a   Carrasquillo, Jorge A ^b   Hoffman, John M ^a   Galen, Barbara ^b   Choyke, Peter ^b   White, Donald E ^a   Rosenberg, Steven A ^a   Sherry, Richard M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer; FDG PET; Imaging; Melanoma; Metastasectomy; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BENIGN TUMOR; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASECTOMY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; TUMOR BIOPSY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; LABORATORY DIAGNOSIS; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; DIAGNOSTIC IMAGING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 6944247966     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2004.01.023     Document Type: Article

References (22)

1. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782-93.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
3. Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001;8:658-62.
4. Health Care Financing Administration. Decision memorandum posted concerning Medicare coverage of FDG positron emission tomography (No. CAG-00065), 12/00 update. Available at: http:// www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=85.
5. 18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996;23:717-35.
6. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
7. Steinert HC, Huch-Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2- deoxy-D-glucose. Radiology 1995;195:705-9.
8. Böni R, Huch-Böni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro- 2-deoxy-D-glucose. Br J Dermatol 1995;132: 556-62.
9. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative study assessing the diagnostic validity in lymph node metastasis of malignant melanoma. Arch Dermatol 1995;131:1394-8.
10. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
11. Wagner JD, Schauwecker D, Davidson D, et al. prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinal node biopsy. J Clin Oncol 1999;17:1508-15.
12. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-6.
13. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
14. Holder WD Jr, White RL, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-71.
15. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18- fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25: 48-51.
16. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinal node biopsy in the detection of micrometastases of primary cutaneous melanoma. J Clin Oncol 2001;19:2674-8.
17. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer 2000;89:1019-25.
18. Eigtved A, Andersson AP, Dhalstrom K, et al. Use of fluorine-18- fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-5.
19. Krug B, Dietlein M, Groth W, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol 2000;41:446-52.
20. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002;9:646-53.
21. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89:389-96.
22. 18F fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91:1530-42.